Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Projected Growth Rate of the Pentavalent Market Through 2029?
The pentavalent market size has grown steadily in recent years. It will grow from $2.62 billion in 2024 to $2.7 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to global immunization initiatives, government vaccination programs, prevention of multiple diseases, public health awareness, international partnerships and funding.
The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.24 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to continued global immunization efforts, expansion of vaccination programs, introduction in new geographies, research and development initiatives, collaborations for vaccine access. Major trends in the forecast period include global health initiatives and funding support, public awareness and education campaigns, government policies and regulatory frameworks, technological innovations in vaccine manufacturing.
Claim your free report sample now:
Which Drivers Are Positively Impacting the Pentavalent Market?
The rising prevalence of diphtheria is expected to boost the growth of the pentavalent market going forward. Corynebacterium diphtheriae is a bacterium that causes the severe, extremely contagious disease known as diphtheria. Diphtheria causes severe difficulties with eating and breathing, as well as the possibility of skin ulcers. The pentavalent vaccine protects children from Diphtheria diseases by a pentavalent immunization in a 3-dose schedule, as a result, the rising prevalence of diphtheria increased the demand for pentavalent vaccines. For instance, in 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, an unusually high number of reported cases of diphtheria were recorded through the International Health Regulations (IHR) reporting process, primarily in the months of June and August 2022. Seven nations have documented 144 instances of diphtheria, many of which were among asylum seekers. Among 144 patients, 97 (69%) were determined to be clinically compatible, 44 (31%) to be toxigenic diphtheria cases by laboratory confirmation, and 3 (2%) were suspected cases. Therefore, the rising prevalence of diphtheria is driving the growth of the pentavalent market.
Which Are the Leading Segments in the Pentavalent Market by Revenue?
The pentavalent market covered in this report is segmented –
1) By Type: Sodium Stibogluconate, Meglumine Antimoniate
2) By Formulation Type: Lyophilized, Liquid
3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Sodium Stibogluconate: Injectable Form, Oral Form, Other Formulations
2) By Meglumine Antimoniate: Injectable Form, Oral Form, Other Formulations
Which Trends Are Most Likely to Influence Pentavalent Market Growth in the Next Decade?
Product innovation has emerged as the key trend gaining popularity in the pentavalent market. Major companies operating in the pentavalent market are developing innovative products to strengthen their position in the market. For instance, in December 2022, Pfizer, a US-based pharmaceutical company, operating in the pentavalent vaccines market got approval from The United States Food and Drug Administration, a US-based federal agency of the Department of Health and Human Services, for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents, indicated for the prevention of meningococcal disease in individuals aged10 to 25. The unique element of the MenABCWY vaccine is the combination of the components of two vaccines into one, helping protect against the meningococcal serogroups that cause the majority of invasive meningococcal diseases.
Who Are the Top Companies Contributing to the Pentavalent Market Expansion?
Major companies operating in the pentavalent market include Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.
Get the full pentavalent market report here:
How Are Market Trends Differentiating Across Key Regions in the Pentavalent Market?
Asia-Pacific was the largest region in the pentavalent market in 2024. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment